Joel F. Sussman

Valeo Medical, Inc. develops non-invasive serum diagnostic for endometriosis, a chronic painful disease that affects women of child-bearing age. It products address the needs of millions of women who suffer with endometriosis. The company was founded by Frederick J. Fritz & Debra A. Peattie in 2003 and is located in Burlington, MA.

NuPathe, Inc. develops pharmaceutical and therapeutic products. It focuses on the development and commercialization of branded therapeutics for diseases of central nervous system, including neurological and psychiatric disorders. The company was founded by Terri B. Sebree and Jane Holmes Hollingsworth in 2005 and is headquartered in Malvern, PA.

Neuro Diagnostic Devices, Inc. provides medical devices. Its product ShuntCheck is an aid to the detection of flow in implanted cerebrospinal fluid (CSF) shunts. The company was founded by Samuel R. Neff and Frederick J. Fritz on May 16, 2005 and is headquartered in Princeton, NJ.

Garnet BioTherapeutics, Inc. develops products that speed healing and reduce scarring after surgery or dermatologic procedures. It is a clinical stage regenerative medicine company that discovers, develops, and delivers new regenerative therapies by leveraging the intrinsic ability of adult somatic cells to repair, regenerate, and remodel tissue in acute and chronic disease settings. The firm's manufacturing and technology platform is a scalable GMP-compliant manufacturing process that can be applied to multiple cell types including adult bone marrow-derived stromal cells, smooth and skeletal muscle cells, dermal fibroblasts, chondrocytes, pre-adipocytes, and endothelial cells. The company was founded by Hubert J.P. Schoemaker on November 26, 2003 and is headquartered in Malvern, PA.

CDNOW, Inc. provides compact discs and other music-related products. It operates as an electronic commerce retailer of pre-recorded music, including compact discs and digital downloads, and other entertainment-related products, as well as a source of entertainment-related content. The company was founded in 1994 and is located in New York.

Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA.